Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Congestive heart failure. New frontiers.

W W Parmley1, K Chatterjee, G S Francis

  • 1Division of Cardiology, University of California, San Francisco.

The Western Journal of Medicine
|April 1, 1991
PubMed
Summary

Congestive heart failure (CHF) remains a significant cause of mortality despite current treatments. Angiotensin-converting enzyme inhibitors show promise in managing CHF, potentially preventing adverse ventricular remodeling after myocardial infarction.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The high-risk patient with heart failure with reduced ejection fraction: treatment options and challenges.

Clinical pharmacology and therapeutics·2013
Same author

Cardiac troponins and chronic kidney disease.

Kidney international·2006
Same author

Plasma BNP concentration predicted the presence of heart failure.

Evidence-based cardiovascular medicine·2005
Same author

Brain natriuretic peptide concentration was effective for screening for LV systolic dysfunction.

Evidence-based cardiovascular medicine·2005
Same author

Pregnancy outcomes during treatment with interferon beta-1a in patients with multiple sclerosis.

Neurology·2005
Same author

Randomized study of once-weekly interferon beta-1la therapy in relapsing multiple sclerosis: three-year data from the OWIMS study.

Multiple sclerosis (Houndmills, Basingstoke, England)·2005

Area of Science:

  • Cardiology
  • Internal Medicine

Background:

  • Congestive heart failure (CHF) is a prevalent syndrome with high mortality, particularly in advanced stages.
  • Current vasodilator therapies prolong life but fail to significantly reduce mortality in severe CHF.
  • Serious arrhythmias contribute to 30-40% of sudden deaths in severe CHF, with antiarrhythmic therapy benefits yet to be established.

Framework:

  • Ventricular remodeling and dilatation post-myocardial infarction (MI) frequently lead to CHF.
  • Early ventricular unloading with angiotensin-converting enzyme (ACE) inhibitors may attenuate these adverse remodeling events.
  • ACE inhibitors demonstrate potential utility across all CHF severities, including left ventricular dysfunction and end-stage disease.

Implementation:

  • Investigating the role of antiarrhythmic therapy in upcoming trials for severe CHF patients.

Related Experiment Videos

  • Utilizing ACE inhibitors for early intervention post-MI to prevent or manage CHF development.
  • Further research into myocardial infarction (MI) mechanisms and treatments, including reperfusion injury, is crucial.

    • Implications:

    • ACE inhibitors offer a promising therapeutic strategy for managing congestive heart failure (CHF) at various stages.
    • Understanding reperfusion injury mechanisms in acute myocardial infarction (MI) could lead to interventions preventing CHF.
    • Addressing arrhythmias in severe CHF is a critical area for future therapeutic development.